March 3, 2025 — Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for treating acute ischemic stroke (AIS) in adults. This approval is Genentech’s second approval for stroke, and the company is now the developer of the only two FDA-approved medicines for AIS, TNKase and Activase (alteplase).

March 1, 202 — One in three people worldwide will develop a potentially life-threatening heart rhythm disorder in their lifetime, yet awareness remains critically low. On March 1 — Pulse Day (Global Arrhythmia Awareness Day) — cardiologists from the European Heart Rhythm Association (EHRA) urged communities and healthcare systems to "Feel the Pulse" and take simple steps to raise awareness of these serious but often overlooked conditions.

Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD), at early adopter imaging centers in the US. This  follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI..

March 3, 2025 — Eko Health has published a peer-reviewed study in JACC Advances evaluating its 

Feb. 25, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD) management, recently introduced its new brand identity reflecting its focus on delivering clarity, precision and confidence in the prevention, diagnosis and treatment of CAD.


Imagine a future where a silent, undetected heart condition is caught before it turns into a life-threatening event — a future where artificial intelligence (AI) -powered insights alert clinicians to warning signs long before symptoms appear. That future isn’t decades away. It is already here.

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive standard dataset of 16 patient-centered outcome measures for people with heart valve disease, regardless of treatment (surgical or transcatheter procedure), according to a new report published in the American Heart Association’s journal Circulation: Cardiovascular Quality & Outcomes.

Feb. 11, 2025  — UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound, recently announced support from Bristol Myers Squibb (BMS) for a study that aims to improve access to echocardiographic assessments for patients with obstructive hypertrophic cardiomyopathy (oHCM).

Cardiac ultrasound is routinely used as an essential tool in the diagnosis and management of oHCM.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now